Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $294.50 Consensus Price Target from Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twenty-four brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eighteen have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $294.50.

Several research firms recently commented on ALNY. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research note on Tuesday. Canaccord Genuity Group lifted their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a report on Friday, November 1st. TD Cowen increased their price target on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Wells Fargo & Company lifted their target price on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an "equal weight" rating in a research report on Friday, August 2nd. Finally, Barclays increased their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a research note on Friday, November 1st.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded down $22.35 during mid-day trading on Friday, reaching $235.56. The company's stock had a trading volume of 1,761,297 shares, compared to its average volume of 875,422. The firm has a market capitalization of $30.38 billion, a PE ratio of -89.91 and a beta of 0.39. The stock has a fifty day moving average of $274.95 and a two-hundred day moving average of $234.30. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same period last year, the firm earned $1.15 earnings per share. The firm's revenue for the quarter was down 33.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -2.22 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company's stock, valued at approximately $20,563,480. This represents a 16.96 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.50% of the company's stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently modified their holdings of ALNY. Allspring Global Investments Holdings LLC raised its stake in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $26,000. Huntington National Bank raised its holdings in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at $29,000. Finally, Altitude Crest Partners Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at about $30,000. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.